International Journal of Cell Biology vol. 285, no. 11, pp. 8463–8471, 2010. [4] A. L. Groeger and B. A. Freeman, “Signaling actions of elec- trophiles: anti-inﬂammatory therapeutic candidates,” Molecu- lar Interventions, vol. 10, no. 1, pp. 39–50, 2010. [5] T. Akaike, S. Fujii, T. Sawa, and H. Ihara, “Cell signaling mediated by nitrated cyclic guanine nucleotide,” Nitric Oxide, vol. 23, no. 3, pp. 166–174, 2010. [6] T. Satoh and S. A. Lipton, “Redox regulation of neuronal survival mediated by electrophilic compounds,” Trends in Neurosciences, vol. 30, no. 1, pp. 37–45, 2007. [7] T. Satoh, S. I. Okamoto, J. Cui et al., “Activation of the Keap1/Nrf2 pathway for neuroprotection by electrophillic phase II inducers,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 3, pp. 768– 773, 2006. [8] T. Satoh, K. Kosaka, K. Itoh et al., “Carnosic acid, a catechol- type electrophilic compound, protects neurons both in vitro and in vivo through activation of the Keap1/Nrf2 pathway via S-alkylation of targeted cysteines on Keap1,” Journal of Neurochemistry, vol. 104, no. 4, pp. 1116–1131, 2008. [9] A. D. Kraft, D. A. Johnson, and J. A. Johnson, “Nuclear factor E2-related factor 2-dependent antioxidant response element activation by tert-butylhydroquinone and sulforaphane occur- ring preferentially in astrocytes conditions neurons against oxidative insult,” Journal of Neuroscience, vol. 24, no. 5, pp. 1101–1112, 2004. [10] R. I. Morimoto, “Proteotoxic stress and inducible chaperone networks in neurodegenerative disease and aging,” Genes and Development, vol. 22, no. 11, pp. 1427–1438, 2008. [11] B. Bukau, J. Weissman, and A. Horwich, “Molecular chaper- ones and protein quality control,” Cell, vol. 125, no. 3, pp. 443– 451, 2006. [12] A. Mart´ınez-Ruiz, S. Cadenas, and S. Lamas, “Nitric oxide sig- naling: classical, less classical, and nonclassical mechanisms,” Free Radical Biology and Medicine, vol. 51, no. 1, pp. 17–29, 2011. [13] U. Forstermann, H. H. H. W. Schmidt, J. S. Pollock et al., “Isoforms of nitric oxide synthase. Characterization and puriﬁcation from diﬀerent cell types,” Biochemical Pharmacol- ogy, vol. 42, no. 10, pp. 1849–1857, 1991. [14] J. R. Steinert, T. Chernova, and I. D. Forsythe, “Nitric oxide signaling in brain function, dysfunction, and dementia,” Neuroscientist, vol. 16, no. 4, pp. 435–452, 2010. [15] R. Sattler, Z. Xiong, W. Y. Lu, M. Hafner, J. F. MacDonald, and M. Tymianski, “Speciﬁc coupling of NMDA receptor activation to nitric oxide neurotoxicity by PSD-95 protein,” Science, vol. 284, no. 5421, pp. 1845–1848, 1999. [16] M. Russwurm and D. Koesling, “NO activation of guanylyl cyclase,” EMBO Journal, vol. 23, no. 22, pp. 4443–4450, 2004. [17] F. Hofmann, “The biology of cyclic GMP-dependent protein kinases,” Journal of Biological Chemistry, vol. 280, no. 1, pp. 1–4, 2005. [18] S. H. Francis, J. L. Busch, and J. D. Corbin, “cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action,” Pharmacological Reviews, vol. 62, no. 3, pp. 525–563, 2010. [19] S. A. Lipton, Y. B. Choi, Z. H. Pan et al., “A redox-based mechanism for the neuroprotective and neurodestructive eﬀects of nitric oxide and related nitroso-compounds,” Nature, vol. 364, no. 6438, pp. 626–632, 1993. [20] V. L. Dawson, T. M. Dawson, E. D. London, D. S. Bredt, and S. H. Snyder, “Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 88, no. 14, pp. 7 6368–6371, 1991. [21] E. Bonfoco, D. Krainc, M. Ankarcrona, P. Nicotera, and S. A. Lipton, “Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D- aspartate or nitric oxide/superoxide in cortical cell cultures,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 16, pp. 7162–7166, 1995. [22] N. Sen, M. R. Hara, A. S. Ahmad et al., “GOSPEL: a neuropro- tective protein that binds to GAPDH upon S-nitrosylation,” Neuron, vol. 63, no. 1, pp. 81–91, 2009. [23] Y. B. Choi, L. Tenneti, D. A. Le et al., “Molecular basis of NMDA receptor-coupled ion channel modulation by S- nitrosylation,” Nature Neuroscience, vol. 3, no. 1, pp. 15–21, 2000. [24] D. T. Hess, A. Matsumoto, S. O. Kim, H. E. Marshall, and J. S. Stamler, “Protein S-nitrosylation: purview and parameters,” Nature Reviews Molecular Cell Biology, vol. 6, no. 2, pp. 150– 166, 2005. [25] J. Qu, T. Nakamura, G. Cao et al., “S-Nitrosylation activates Cdk5 and contributes to synaptic spine loss induced by beta- amyloid peptide,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 34, pp. 14330–14335, 2011. [26] T. Uehara, T. Nakamura, D. Yao et al., “S-Nitrosylated protein- disulphide isomerase links protein misfolding to neurodegen- eration,” Nature, vol. 441, no. 7092, pp. 513–517, 2006. [27] M. Benhar, M. T. Forrester, and J. S. Stamler, “Protein den- itrosylation: enzymatic mechanisms and cellular functions,” Nature Reviews Molecular Cell Biology, vol. 10, no. 10, pp. 721– 732, 2009. [28] F. M. LaFerla, K. N. Green, and S. Oddo, “Intracellular amyloid-β in Alzheimer’s disease,” Nature Reviews Neuro- science, vol. 8, no. 7, pp. 499–509, 2007. [29] D. J. Selkoe, “Alzheimer’s disease is a synaptic failure,” Science, vol. 298, no. 5594, pp. 789–791, 2002. [30] R. D. Terry, E. Masliah, D. P. Salmon et al., “Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment,” Annals of Neurology, vol. 30, no. 4, pp. 572–580, 1991. [31] D. Harman, “Aging: a theory based on free radical and radiation chemistry,” Journal of Gerontology, vol. 11, no. 3, pp. 298–300, 1956. [32] K. B. Beckman and B. N. Ames, “The free radical theory of aging matures,” Physiological Reviews, vol. 78, no. 2, pp. 547– 581, 1998. [33] L. M. Sayre, G. Perry, and M. A. Smith, “Oxidative stress and neurotoxicity,” Chemical Research in Toxicology, vol. 21, no. 1, pp. 172–188, 2008. [34] M. M. Lyles and H. F. Gilbert, “Catalysis of the oxidative folding of ribonuclease A by protein disulﬁde isomerase: pre-steady-state kinetics and the utilization of the oxidizing equivalents of the isomerase,” Biochemistry, vol. 30, no. 3, pp. 619–625, 1991. [35] M. M. Lyles and H. F. Gilbert, “Catalysis of the oxidative folding of ribonuclease A by protein disulﬁde isomerase: dependence of the rate on the composition of the redox buﬀer,” Biochemistry, vol. 30, no. 3, pp. 613–619, 1991. [36] R. J. Kaufman, “Stress signaling from the lumen of the endoplasmic reticulum: coordination of gene transcriptional and translational controls,” Genes and Development, vol. 13, no. 10, pp. 1211–1233, 1999. [37] W. Scheper and J. J. M. Hoozemans, “Endoplasmic reticulum protein quality control in neurodegenerative disease: the good, the bad and the therapy,” Current Medicinal Chemistry, vol. 16,